Contact us to learn more about partnering opportunities

BerGenBio is a premier partner for pharmaceutical companies seeking to drive efficiencies and derisk their drug discovery programs

CELLSELECT RNAi

CellSelectRNAi is a suite of technologies for the production and screening of large libraries of shRNA RNA interference elements.

Typically we produce and screen 100-300 shRNAs per target gene, guaranteeing not only identification of several highly effective shRNAs but also a collection of shRNAs that trigger a range of lesser knockdowns, producing an ‘epi-allelic series’.

Features

  • “Ask The Cell” phenotypic genetic screening
  • 100-300 shRNA per gene
  • Multiple effective RNAi sequences to guard against off-target effects
  • Retroviral delivery for reliable sustained knockdown
  • Single gene, gene family or druggable-genome scale libraries

Example Applications

Single gene libraries

  • Drug target validation in in vivo/in vitro models
  • Epi-allelic analysis to determine required inhibition for therapeutic effect
  • Long term in vivo studies
  • Mechanism of action studies

Gene family libraries

  • Validation of true target of promiscuous drug
  • Mimic effects of promiscuous drugs by mimicking different degrees of knockdown for each target

Druggable-genome libraries

  • Dominant effector genetic screening for complex phenotypes
  • Novel drug target candidate discovery, therapeutic mechanism of action studies
Print